Last updated: February 20, 2026
The CAREFUSION 2200 infusion pump is a critical device within hospital infusion therapy. Its market landscape is shaped by product features, regulatory approvals, competing technologies, and strategic positioning among healthcare providers.
Market Position Overview
The CAREFUSION 2200, produced by Becton Dickinson (BD), entered the infusion pump market in the early 2010s. It caters to hospitals seeking reliable infusion control with advanced safety features. The device is characterized by its versatility, supporting both primary and secondary infusion modalities, including IV, PCA, and blood transfusions.
Market penetration has been concentrated in North America and parts of Europe, driven by hospital procurement processes, compliance needs, and integration capabilities with electronic health records (EHR). According to BD’s 2022 annual report, the device was part of BD's broader infusion therapy segment, which generated approximately $2.7 billion in revenue.
Competitive Landscape
The main competitors include:
| Vendor |
Key Pump Models |
Market Share (Estimated) |
Unique Selling Points |
| Carefusion (BD) |
2200 |
25% |
Proven safety features, integration capabilities |
| B. Braun |
Perfusor, Spirit |
20% |
Lower cost, modular design |
| Baxter |
Sigma Spectrum |
15% |
Remote management, user-friendly interface |
| Terumo |
Surguard |
10% |
Compact size, reliability |
| Others |
Various |
30% |
Niche and emerging solutions |
Market share estimates derive from industry reports (MedTech Insight, 2022). The CAREFUSION 2200 maintains competitive advantage through its safety algorithms, compliance with strict FDA and EMA regulations, and compatibility with hospital IT systems.
Product Strengths
-
Safety Features: Override-resistant lockouts, dose error reduction systems (DERS, DERS2), and real-time monitoring minimize medication errors.
-
Flexibility: Supports a broad range of infusion modalities, including PCA, blood transfusions, and continuous infusion.
-
User Interface: Touchscreen control with customizable workflows reduces setup time and training needs.
-
Connectivity: Integration with electronic health records enhances documentation and reduces manual entry errors.
-
Regulatory Approvals: Approved by FDA (2013) and CE marked, facilitating hospital acceptance across key markets.
Strategic Insights
Market Expansion Opportunities
The device's existing features align with hospital initiatives for safety and automation. Growth can be driven by expanding into emerging markets via partnerships and localized compliance strategies, especially in Asia-Pacific where hospital infrastructure investments increase.
Innovation Pathways
Investing in smart infusion systems integrating AI for predictive infusion management could position the CAREFUSION 2200 as a future-ready platform. Developing wireless connectivity and advanced analytics capabilities can meet increasing demands for real-time data.
Competitive Differentiators
- Safety Leadership: Reinforcing safety features against competitors with standard-function pumps offers differentiation.
- EHR Integration: Seamless connectivity with hospital systems enhances workflow efficiency, appealing to hospitals transitioning to digital platforms.
- Cost-Effectiveness: Competitive pricing, combined with high safety standards, can influence procurement decisions, especially in cost-sensitive markets.
Challenges
- Price pressure from competitors offering lower-cost models.
- Slow adoption of new software features due to regulatory and procurement cycles.
- Maintenance and service costs impacting total cost of ownership (TCO).
Conclusion
The CAREFUSION 2200 holds a solid market position through its safety, flexibility, and IT compatibility. Continued growth depends on expanding geographic presence, pursuing technology advancements, and emphasizing safety as a differentiator.
Key Takeaways
- Holds approximately 25% market share in infusion pumps within select regions.
- Strengths lie in safety features, flexible infusion modes, and integration.
- Growth opportunities exist in emerging markets and via digital health innovations.
- Competitive landscape is dominated by B. Braun, Baxter, and Terumo, with price and safety as key differentiators.
- Challenges include pricing pressure and slow adoption of advanced features.
FAQs
1. What regulatory approvals does the CAREFUSION 2200 hold?
FDA clearance (2013) and CE marking, enabling sales in North America and Europe.
2. How does safety influence market competitiveness?
Safety features such as dose error reduction and lockout mechanisms are primary differentiators and influence hospital procurement decisions.
3. What are the main growth drivers for CAREFUSION 2200?
Hospital investments in digital infrastructure, safety initiatives, and expansion into emerging markets.
4. How does the device compare in terms of connectivity?
It offers integration with hospital EHR systems, supporting real-time data exchange to reduce manual errors.
5. What are the main barriers to market expansion?
Price competition, regulatory delays for new software features, and maintenance costs.
References
- MedTech Insight. (2022). Infusion Therapy MarketShare Analysis.
- BD. (2022). Annual Report on Infusion Devices.
- U.S. Food and Drug Administration. (2013). FDA Approval Documents for CAREFUSION 2200.
- European Medicines Agency. (2014). CE Mark Certification Details.
